Article in The American journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06864403 phase4recruitingnot on this mapstarted 2025, after this paper: background citation
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2025 to 2027Enrolled25ConditionsPouchitis, Pouches, Ileoanal, Pouch, IlealArmsMirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
NCT07756359 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2026 to 2027Enrolled20ConditionsPouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryArmsTirzepatide, Loperamide, Diphenoxylate/Atropine
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Maia KayalDivision of Gastroenterology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Parakkal DeepakDivision of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.ORCID 0000-0002-3436-9784
Poonam Beniwal-PatelDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Laura RaffalsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Marla DubinskyDivision of Pediatric Gastroenterology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4968-5795
Shannon ChangDivision of Gastroenterology and Hepatology, NYU Langone Health, New York, New York, USA.ORCID 0000-0001-6195-5386
Peter D R HigginsDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Yue JiangTrinity College of Arts and Sciences, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-8334-0013
Raymond K CrossDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-9766-5196
Millie D LongDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Hans H HerfarthDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4268-823
Edward L BarnesDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-9894-8796
Funding
Treatment Approaches and Outcomes in Pouch-related Disorders after Colectomy for Ulcerative ColitisK23DK127157 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARNES, EDWARD · 2021 to 2025
$1.0M
Characterizing the Biologic Evolution of Crohn's Disease Like Pouch Inflammation in Ulcerative Colitis Patients After Restorative Proctocolectomy with Ileal Pouch Anal AnastomosisK23DK127241 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Maia Kayal · 2022 to 2026
introductionThere is a paucity of data on the real-world effectiveness of therapies in patients with Crohn's disease of the pouch.
methodsThis was a prospective multicenter study evaluating the primary outcome of remission at 12 months of therapy for Crohn's disease of the pouch.
resultsOne hundred thirty-four patients were enrolled. Among the 77 patients with symptoms at baseline, 35 (46.7%) achieved remission at 12 months. Of them, 12 (34.3%) changed therapy. There was no significant association between therapy patterns and remission status. DISCUSSION: Approximately 50% with symptoms at enrollment achieved clinical remission at 12 months, most of whom did so without a change in therapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the Pouch. · full record | OpenQuestion